Phase 3 N=85 Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury
Stress Disorders, Posttraumatic
Primary: PTSD Symptoms in Children 6 Weeks Post-injury — 12.6; 13.6 Units on a scale — p=.69
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=127 Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 50.0; 76.5; 86.7; 90.3 percentage of participants
Phase 2 N=25 Cognitive Behavioral Therapy (CBT) for Tinnitus
Tinnitus
Primary: Tinnitus Handicap Inventory (THI) — 37.9; 45.1; 42.67; 26.0 units on a scale of 0-100 — p=<0.05
Phase 3 N=60 The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome · Hypovitaminosis D
Primary: Ultrasound Examination of Number of Follicles and Ovarian Volume — 7; 0; 5; 11 participants — p=0.001
N/A N=31 Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 10.94; 13.93 units on a scale
N/A N=6 Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy
Localize Liver Metastases
Primary: Number of Participants Eligible for Cone Beam Tumor Localization" — 5 participants
Phase 3 N=532 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. — -12.24; -14.17; -0.95 Score on a scale — p=<0.0001
Phase 2 N=71 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Prolymphocyctic Leukemia
Primary: Percentage of Participants Achieving Response — 92.6; 80.0; 70.8 percentage of participants
Phase 3 N=130 Nortriptyline for Idiopathic Gastroparesis
Idiopathic Gastroparesis
Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86
Phase 4 N=20 Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands
Purpura
Primary: Reduction of Bruising — 3.74; 4.50 cm squared
N/A N=34 Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Intensive Care Unit · Muscle Weakness
Primary: Lower Extremity Strength, at Hospital Discharge, of 3 Bilateral Muscle Groups (Pretibial, Triceps Surae, and Quadriceps) Measured Via MMT Using a Composite Medical…
Phase 3 N=607 Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
Vesicoureteral Reflux · Urinary Tract Infections
Primary: Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up — 39; 72 participants — p=<0.001
Phase 4 N=206 Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery
Pain, Postoperative
Primary: Total Opioid Consumption Measured in Intravenous Morphine Equivalents During the Postoperative Hospital Stay — 17.3; 15 mg (morphine equivalents) — p=0.39
Phase 2 N=55 A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Ratio of TNF Alpha at Week 6 to Baseline — 1.37; 1.21 ratio
N/A N=29 Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control
Diabetes Mellitus, Type 2
Primary: Glycemic Control — 144; 172 mg/dL